Rolapitant

Generic name: Rolapitant (oral)
Brand names: Varubi
Dosage form: oral tablet (90 mg)
Drug class: NK1 receptor antagonists

Usage of Rolapitant

Rolapitant is used together with other medicines to prevent nausea and vomiting caused by cancer chemotherapy.

Rolapitant may also be used for purposes not listed in this medication guide.

Rolapitant side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Rolapitant may cause serious side effects. Call your doctor at once if you have:

pain or burning when you urinate;

low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or

low white blood cell counts--fever, swollen gums, painful mouth sores, skin sores, cold or flu symptoms, cough, trouble breathing.

Common side effects of rolapitant may include:

low blood cell counts;

painful urination;

mouth sores;

hiccups;

dizziness; or

stomach pain, indigestion, loss of appetite.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Rolapitant

Some medicines can cause unwanted or dangerous effects when used with rolapitant. Your doctor may change your treatment plan if you also use:

pimozide; or

thioridazine.

Rolapitant is not approved for use by anyone younger than 2 years old.

Tell your doctor if you have ever had:

liver disease; or

if you use a blood thinner (such as warfarin) and you have routine "INR" or prothrombin time tests.

Tell your doctor if you are pregnant or breastfeeding.

rolapitant may affect fertility (your ability to have children) for a short time.

Relate drugs

How to use Rolapitant

Usual Adult Dose for Nausea/Vomiting -- Chemotherapy Induced:

Oral: 180 mg orally within 2 hours prior to initiation of chemotherapy on Day 1Parenteral: 166.5 mg via IV infusion (over 30 minutes) within 2 hours prior to initiation of chemotherapy on Day 1ADDITIONAL MEDICATIONS:Highly Emetogenic Cancer Chemotherapy (HEC):-Day 1: Dexamethasone 20 mg orally 30 minutes prior to chemotherapy; 5-HT3 antagonist per treatment guideline-Days 2 to 4: Dexamethasone 8 mg orally 2 times a dayModerately Emetogenic Cancer Chemotherapy (MEC):-Day 1: Dexamethasone 20 mg orally 30 minutes prior to chemotherapy; 5-HT3 antagonist per treatment guidelinesComments:-Additional 5-HT3 antagonist doses may be administered per treatment and manufacturer guidelines.-The manufacturer product information for appropriate dosing information for these drugs.-This dose should be given at the beginning of chemotherapy, and at no less than 2-week intervals.Use: In combination with other antiemetic agents for prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including HEC

Warnings

Tell your doctor about all your current medicines and any you start or stop using. Many drugs can interact, and some drugs should not be used together.

What other drugs will affect Rolapitant

For at least 28 days after you use rolapitant, it could affect other medicines you are using.

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Many drugs can affect rolapitant, and some drugs should not be used at the same time. Tell your doctor about all your current medicines and any medicine you start or stop using. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.